Indicated for: cancer
Route of administration: oral
Substance: selumetinib (tyrosine kinase inhibitor)
ATC: L01EE04 (Antineoplastic and immunomodulating agents | Protein kinase inhibitors | Mitogen-activated protein kinase (MEK) inhibitors)
This medicine may affect fertility.
Handle with special care.
Effective contraception is required during treatment.
Do not use this medicine while breastfeeding.
Do not use this medicine during pregnancy.
Avoid grapefruit and grapefruit juice.
This medicine may affect the liver.
This medicine may have important interactions with other medicines.
This medicine may lower blood cell counts.
This medicine is subject to additional monitoring.
Periodic laboratory tests may be required during treatment.
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
This medicine may increase the risk of heart rhythm disturbances.
Selumetinib is a medication used for the treatment of neurofibromatosis type 1 (NF1) in pediatric patients with symptomatic plexiform neurofibromas. It acts as an inhibitor of MEK1 and MEK2 kinases, reducing tumor growth and associated symptoms.
The medication is taken orally, as directed by a doctor, usually twice daily. It is important for patients to follow the treatment regimen and undergo regular check-ups to monitor the response to therapy.
Patients should be aware of potential side effects, such as nausea, diarrhea, or elevated liver enzyme levels. It is important to inform the doctor of any unusual symptoms.
Common side effects include nausea, diarrhea, and elevated liver enzyme levels. In rare cases, severe reactions such as liver failure or allergic reactions may occur. Patients should be informed of these risks before starting treatment.